Additional GPCR Expressing Cell Lines Released

Lonza Releases Four New GPCR Expressing Cell Lines

 

Now available!  New cell lines for GPR103 and Vasopressin receptors V1a, V1b, and V2 allow you to evaluate excellent GPCR response levels at competitive prices. New receptors are available for the following therapeutic areas: increased feeding, blood pressure, bone formation, cell proliferation, glycogenolysis, and antidiuretic action.  Please review these GPCRs or our growing list of other GPCR products by going to our e-catalog. Place an order for any of the 4 products listed in this e-mail by October 30, 2007 and reference the code GPCRT207 to receive a 15% discount from list price. >> Human GPR103 Cell Line GPR103 is a G-protein coupled receptor that has been shown to be expressed primarily in brain, heart, kidney, adrenal gland, retina and testis. Its ligand has been identified as a 43-residue RF-amide peptide known as QRFP. >> Human Vasopressin V1a Receptor Cell Line The pituitary hormone vasopressin (AVP) is a cyclic nonapeptide that acts by binding to a family of vasopressin receptors that includes the V1a, V1b, and V2 receptors. V1a receptors have been shown to be expressed in vascular smooth muscle, hepatocytes, various blood cells, brain, and retina. >> Human Vasopressin V1b Receptor Cell Line The pituitary hormone vasopressin (AVP) is a cyclic nonapeptide that acts by binding to a family of vasopressin receptors that includes the V1a, V1b, and V2 receptors. V1b receptors are expressed in the anterior pituitary where they mediate ACTH release. >> Human Vasopressin V2 Receptor Cell Line V2 receptors are expressed in the kidney where vasopressin exerts its antidiuretic action.